Tauroursodeoxycholic
Cholestatic Liver Disease
Beijing Trendful Kangjian Medical Information Consulting Limited CompanyPhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Cholestatic Liver Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Linerixibat GlaxoSmithKline | Phase 3 | BB |
URSODEOXYCHOLIC ACID Assistance Publique - Hôpitaux de Paris | Phase 3 | BB |
lum001 Mirum Pharmaceuticals, Inc. | Phase 3 | BB |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 3 | B |
ERGOCALCIFEROLUM Chulalongkorn University | Phase 4 | B |
View all 24 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →